| Dear Reader, Today is the big day I’ve been looking forward to for months and months. We’re launching our new division, Health & Wealth Research. Check it out here. Health and wealth are two essential elements of a good life. I believe the entire healthcare sector, including pharma and biotech companies, will offer many potentially profitable, and some extraordinarily profitable, opportunities to rifle shot our investments over the next decade. Let me quickly note, simply buying an index in what is supposedly a growing industry may not be the answer this time. Old Pharma is going to be seriously disrupted and, with a few exceptions, will not be where you want to be. I am not alone in that assessment. A November 15 CNBC article states that healthcare is one of the preferred investments of the ultra-wealthy. I can confirm that when I'm invited to meetings of serious investors, biotech keeps coming to the top of the conversation. “It’s the gift that keeps on giving,” said Michael Sonnenfeldt, founder of the investment club Tiger 21, whose more than 600 members are entrepreneurs from all industries. “If you cure cancer, in good times and in bad, you’re going to have a winner.” He also pointed out that there’s “huge wealth” in the US and that people will happily pay to improve their quality of life. He’s right. That’s why I’ve been advocating for years for Mauldin Economics to build its own “health sector” division. And so it has. Since the website is brand new, please do me a favor: If you notice any glitches or links that don’t work, please let us know at healthandwealth@mauldineconomics.com. As I’ve told you before, we’ve added two experts whose research will complement my friend Patrick Cox’s biotech analysis: - Chris Wood, one of my favorite healthcare analysts. Chris will cover the companies he believes are poised to solve the biggest health challenges facing society today. Think cancer, Alzheimer’s disease, diabetes. He is laser focused on and hyper-connected with the businesses that occupy these sectors.
- ... and Dr. Michael Roizen, MD, chief wellness officer at the Cleveland Clinic, chief medical consultant for The Dr. Oz Show, author of numerous books selling over 30 million copies and, as it happens, my personal physician.
While Chris attends to the wealth side of the business, Dr. Mike is an authority on disease prevention and wellness. With him as your guide, you’ll be able to avoid the health problems that our portfolio companies make an effort to treat. [Personal note: Dr. Mike and I talk at least twice a week. Not just about my ailments and meds (which are rather boring conversations), but about the broader aspects of life and healthcare, where the challenges are and where the opportunities will be. Nobody is as connected as he in the healthcare providing business.] If you have signed up for Chris’s free weekly letter, A Rich Life, you should see the inaugural issue in your inbox today. If you haven’t, you can do so here. Patrick Cox and Dr. Mike will also be regular contributors to A Rich Life. Dr. Mike has generously allowed us to use an excerpt from his book, YOU the Smart Patient, as the proverbial carrot for you to sign up. You’ll get this report we call 25 Questions You Must Ask at the Hospital immediately after you sign up for A Rich Life. And on December 18, you’ll get a chance to see Chris Wood’s new health investing letter, Healthy Returns, which focuses on mid- to large-cap companies in the healthcare, pharma, and biotech arenas. Aside from investment research, every issue of Healthy Returns will also contain a section with pertinent health and wellness advice from Dr. Mike. Our “grand opening” of this newsletter will come with a charter offer that you should seriously consider. Your excited about our new division analyst, Sincerely, 
John Mauldin | 